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Objectives: To compare the effectiveness of peripheral nerve stimulation utilizing a subcutaneous lead implant technique—
subcutaneous nerve stimulation (SQS) plus optimized medical management (SQS1OMM arm) vs. optimized medical manage-
ment alone (OMM arm) in patients with back pain due to failed back surgery syndrome.
Patients and Methods: Patients were recruited from 21 centers, in Europe, Israel, and Australia. Eligible patients were random-
ized (1:1) to SQS1OMM or OMM arms. Those in the SQS arm were implanted with a neurostimulator and up to two
subcutaneous percutaneous cylindrical leads in the area of pain. Patients were evaluated pre-randomization and at one, three, six,
and nine months post-randomization. The primary endpoint was the proportion of subjects with a 50% reduction in back pain
intensity (“responder”) from baseline to nine months. Secondary outcomes included proportion of responders with a 50%
reduction in back pain intensity at six months and 30% reduction at nine months, and the mean change from baseline in back
pain intensity at six and nine months between the two arms.
Results: Due to the slow rate of recruitment, the study was terminated early with 116 subjects randomized. A total of 33.9% (19/
56, missing: n5 20 [36%]) of subjects in the SQS1OMM arm and 1.7% (1/60, missing: n5 24 [40%]) in the OMM arm were
responders at Month 9 (p< 0.0001). Secondary objectives showed a significant difference in favor of SQS1OMM arm.
Conclusion: The results indicate that the addition of SQS to OMM is more effective than OMM alone in relieving low back pain at
up to nine months.
Keywords: Back pain, failed back surgery syndrome, peripheral nerve field stimulation, randomized controlled trial, subcutaneous
stimulation
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INTRODUCTION
Failed back surgery syndrome (FBSS) is defined as persistent low
back and/or leg pain after technically and anatomically successful
lumbar spine surgery (1). Most patients with FBSS suffer from mixed
back and leg pain, which is often of a combined neuropathic and
nociceptive nature. Some patients suffer with a predominant leg or
back pain component. Back pain following lumbar surgery is more
likely to have a neuropathic component than back pain without pre-
ceding surgery (2).
Regardless of the cause, chronic back pain can be debilitating and
difficult to treat. It can interfere with emotional, physical, and social
components of life, including mood, quality of life, daily activities,
sleep, and the ability to work (3). Patients suffering from chronic
pain of neuropathic origin following FBSS often fail to obtain ade-
quate relief with conventional therapies (e.g., medication, nondrug
therapies) and suffer greater pain and lower health-related quality of
life compared to patients with other chronic pain conditions (4).
Treatment for chronic pain may include pharmacologic and non-
pharmacologic treatments (e.g., physical therapy, cognitive-
behavioral therapy, nerve block) (5,6). More invasive treatments vary
dependent on the underlying cause of the chronic pain. Reoperation
may be indicated for some patients (7). Patients with intractable
pain who cannot be managed with medications and/or other con-
servative treatments alone may be considered for an implant of neu-
rostimulation therapy or intrathecal drug delivery pump. Traditional
spinal cord stimulation (SCS) has demonstrated success in the treat-
ment of patients with FBSS presenting with predominant leg pain
(8,9); however, the evidence for its efficacy in patients with predomi-
nant or pure low back pain remains inconclusive (6).
One small randomized controlled trial (RCT) and a number of lon-
gitudinal studies reported success in the treatment of low back pain
in FBSS using what has now become known as peripheral nerve
field stimulation (PNFS) using subcutaneously placed leads in the
area of the pain (10–16). The SubQStim Study is a RCT designed to
compare the effectiveness of PNFS, referred to as subcutaneous
nerve stimulation (SQS) plus optimized medical management
(OMM) vs. OMM alone in patients suffering from back pain due to
FBSS. This is the first RCT comparing SQS to OMM and the largest
RCT of SQS published to date. We present here the primary safety
and effectiveness outcome results of the SubQStim study.
PATIENTS AND METHODS
Study Design
The SubQStim study was a pragmatic, prospective, multicenter,
randomized, parallel-arm study (ClinicalTrials.gov Identifier
NCT01711619). Patients were randomized (1:1 ratio) to either the
SQS1OMM arm or the OMM alone arm using random, permuted
blocks methods stratified by groups of two sites. Blinding was not
possible given that SQS therapy was based on the subject receiving
the perception of paresthesia and the nature of the comparative
effectiveness study design. As such, the study was an unblinded,
open-label design. The study was conducted in 25 sites across
Europe, Israel, and Australia, and in accordance with ISO 14155 and
under the approval of each sites’ ethics committee. The study proto-
col was published elsewhere (17).
In its entirety, the study was conceived to include two periods,
first a nine-month two parallel arm randomization phase and an
open-label long-term follow-up period to 36 months as described
previously (17). After nine months, qualifying subjects could cross-
over arms if they wished and returned for visits at 12, 18, 24, 30, and
36 months. This paper reports on the effectiveness outcomes of the
randomization phase (9 months) and safety throughout the study
period (36 months).
Patients
Key inclusion criteria at screening included adults (age 18 or older)
diagnosed with FBSS (i.e., persistent pain for six months following
most recent back surgery, no further therapeutic surgical options,
intractable back pain), who are willing and able to comply with the
study requirements and are an appropriate implant candidate for
the SQS system. Subjects meeting the screening eligibility criteria
completed a baseline diary questionnaire for five to ten days. To
qualify for the study by demonstrating predominant back pain, the
individual must have additionally reported an average back pain
score 50 mm, average leg pain score 30 mm on a 0–100 mm
visual analog scale (VAS), and completed the diary for at least five
days.
Key exclusion criteria included patients currently or previously
treated with implantable neurostimulation or intrathecal drug deliv-
ery system; evidence of an active disruptive psychiatric disorder; any
pain condition unrelated to FBSS severe enough to overshadow the
FBSS pain; spinal fusion at more than three vertebral levels; enroll-
ment in concurrent study; known allergy or hypersensitivity to
device materials; history of coagulation disorder or lupus erythema-
tous; or involved in current litigation regarding their back pain.
Treatments
Subjects randomized to both arms had their medical manage-
ment optimized during the study period, beginning at randomiza-
tion. OMM for each subject was defined by the investigator, but
specifically excluded additional back surgery or the implantation of
medical devices (e.g., other neurostimulation or intrathecal drug
delivery therapies). OMM treatments could vary by subject, such as
by type, frequency, duration, or dose.
Subjects randomized to SQS1OMM first underwent a trial period
with placement of the subcutaneous leads in the area of pain pow-
ered by an external neurostimulator. A maximum of two leads (1 3
8 Standard or PiscesVR Quad Plus, Medtronic, Minneapolis, MN, USA)
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could be implanted. Investigators could choose how many and
what type of leads to use in order to provide the best paresthesia
coverage of the painful area. A comfortable paresthesia within the
area of back pain was deemed necessary, but a minimum percent-
age of coverage was not required by the protocol in order to pro-
ceed with implant.
A successful trial was defined as back pain reduction of >30% as
measured by VAS OR subject had some reduction in pain as mea-
sured by VAS, along with improved function or quality of life, or a
reduction in pain medications as assessed by the investigator. In
addition, subjects must also describe paresthesia as comfortable
and agree to proceed to final implant.
The subcutaneous electrodes and stimulators were implanted
using the standard technique described in the product manuals.
Subjects who met trialing success criteria proceeded to permanent
implant of a rechargeable or nonrechargeable neurostimulator. Sub-
jects could adjust settings and therapy delivery to receive as much
(i.e., 24 hours per day) or as little stimulation as necessary to obtain
pain relief.
Outcomes
The primary objective was to demonstrate that compared to
OMM alone, a higher proportion of subjects with SQS1OMM were
responders (defined as 50% reduction in back pain intensity from
baseline to nine-month follow-up). Secondary objectives were to
demonstrate a greater average decrease in back pain intensity with
SQS1OMM than OMM alone from baseline to the six- and nine-
month follow-up visits, and assess the proportion of subjects
(responders) with 50% reduction in back pain intensity at the six-
month follow-up visit and 30% reduction in back pain intensity at
the nine-month visit.
The VAS was utilized as the endpoint measurement for the pri-
mary and secondary objectives. Both back and leg pain VAS meas-
urements were collected three times per day on a diary for seven
days prior to the three-, six-, and nine-month follow-up visits. The
average pain intensity for each visit was calculated as the average
VAS available during that period. Decrease in pain intensity from
baseline was calculated as v5(100*(VAS02VASv))/VAS0 where
VAS0 is the VAS assessment associated to the baseline and VASv is
the VAS assessment associated to visit V.
Additional outcome measures assessed the difference between
arms and/or change from baseline for leg pain, functional disability
using the oswestry disability index (ODI) (18), European quality of
life five dimensions (EQ-5D-5L) (19), quality of life short form-36
questions (SF-36) (20), patient global impression of change (PGIC)
(21), subject satisfaction, healthcare utilization, and pain medica-
tions. Safety included a characterization of all adverse events and
device deficiencies (as defined in ISO 14155) collected throughout
the study period.
Statistical Analysis
The approach to sample size calculation has been previously
described (17). The original plan was to enroll up to 400 subjects to
obtain 314 evaluable subjects (taking into account screen or base-
line failures and post-randomization attrition). Two interim analyses
were planed after, respectively, 140 and 220 subjects had evaluable
nine-month assessments complete. The software package SAS (ver-
sion 9.3, SAS Institute, Cary, NC, USA) was used for all data analyses
and figures were created using R software (version 3.3.3, Auckland,
New Zealand).
The primary analysis followed the intent-to-treat (ITT) principle for
the primary and secondary objectives, i.e., comparison of arms
according to randomized allocation in subjects. Additionally, per-
treatment (PT) and modified ITT analyses were also performed. The
PT dataset consists of the ITT patient set for whom no major proto-
col deviation was reported. If no major deviation was reported,
patients were analyzed according to the last treatment they received
before the actual assessment. The modified ITT included the ITT
patients to whom the following modifications were applied: (1) sub-
jects randomized to the SQS1OMM arm but not definitively
implanted were considered as “failures” at six and nine months if
the visit is reached; (2) subjects who have passed six- or nine-month
follow-up visits with missing data for six- or nine-month visits were
considered as “failures” if randomized to the SQS1OMM arm and
as “success” if randomized to the OMM arm. No imputation of data
was undertaken if the visit was not reached.
One interim analysis was performed after the decision of early ter-
mination, but prior to communication of the decision to study cen-
ters. To preserve an overall alpha error risk of 5%, the final analysis
was run at a nominal alpha of 4% and the interim analysis at 1%.
Results are reported as means and standard deviations or 95%
confidence intervals. Difference in responder rates were tested
through Fisher’s exact test. Differences between absolute change
from baseline were tested using linear mixed model including values
at baseline, treatment and visit information, and treatment visit
interaction. If not otherwise mentioned, p-values presented in the
text correspond to the overall treatment effect being different from
zero.
RESULTS
In February 2016, due to prolonged recruitment challenges, the
study sponsor chose to terminate the study prior to completing
enrollment. The decision was endorsed by the Trial Steering Com-
mittee prior to performing any interim data analyses. The decision
was not based on any concerns about patient safety or product reli-
ability. Prior to termination, 162 subjects were enrolled (consented),
between January 2013 and January 2016 in 21 sites, of which 116
were randomized: 56 in the SQS1OMM arm and 60 in the OMM
arm. Due to early study termination, subjects were not provided an
opportunity to complete the study and attend all visits, thus sub-
jects were discontinued at various time points in the study with 74
completing the nine-month primary endpoint visit (Fig. 1). Enroll-
ment by site is provided in Supporting Information Table S1.
Demographic Characteristics
At baseline both arms were similar for demographic data
(Table 1). Pain was likely neuropathic (Douleur Neuropathique 4
score 4) in 48.2% of subjects. Subjects reported relatively low
health-related quality of life (EQ-5D-5L UK index: 0.416 0.23; EQ-
5D-5L-VAS: 43.6 mm6 21.2) and severe disability (mean ODI:
49.46 12.7).
Of the 56 subjects randomized to SQS1OMM, 52 underwent the
test stimulation procedure. Mean test stimulation duration was
16.06 8.7 days (range 4–36). The longer duration is in part due to
legal Belgian requirements for a 28-day trial period. Excluding sub-
jects from Belgian sites, the mean duration moderately reduces to
13.56 7.0 days (range 4–34). One individual did not start the testing
period due to early study termination and three others were discon-
tinued prematurely for other reasons. Of the 52 implanted, 51 com-
pleted the test stimulation phase (one individual did not complete
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Table 1. Demographics.
Variable SQS1OMM OMM All
n5 56 n5 60 N5 116
Age at inclusion (years; mean6 SD) 50.96 10.9 52.26 11.4 51.66 11.1
Gender male (N, %) 24 (42.9%) 26 (43.3%) 50 (43.1%)
Time since onset of back pain (years; median [minimum; maximum]) 9.0 [1;48] 9.5 [2;40] 9.0 [1;48]
Time since onset of back pain (years; mean6 SD) 13.56 11.0 13.16 9.9 13.36 10.4
Back pain intensity at baseline (VAS 0–100 mm; mean6 SD) 68.86 13.4 70.16 14.0 69.56 13.7
Leg pain intensity at baseline (VAS 0–100 mm; mean6 SD) 8.96 10.8 6.86 11.5 7.86 11.2
Time since last spinal surgery (years; mean6 SD) 5.16 5.1 6.36 6.8 5.76 6.1
Previous lumbar or lower thoracic spinal surgeries by subject (mean6 SD) 2.66 1.6 2.56 1.5 2.56 1.5
Number of previous back pain drug categories of treatments tried (mean6 SD) 5.56 2.4 5.06 2.6 5.26 2.6
Number of nonsurgical, nonpharmaceutical back pain categories of treatments tried (mean6 SD) 4.16 2.3 3.66 2.2 3.86 2.3
SD, standard deviation.
Figure 1. CONSORT diagram of patient flow.
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the test stimulation phase due to early termination of the study). Of
the 51 subjects completing the test stimulation phase, 46 (90.2%)
had a successful trial and agreed to proceed to permanent implant.
As a reason to not proceed to implant, five (9.8%) had no significant
pain reduction. Only one subject found the feeling of paresthesia
uncomfortable.
Of the 46 subjects that agreed to proceed to permanent implant,
45 were successfully implanted. One individual who had a successful
trial discontinued the study due to an adverse event unrelated to
the therapy.
For those subjects permanently implanted (n5 45), 32 (71.1%)
had the test stimulation leads remain in place (i.e., buried or defini-
tive lead trial), whereas 13 (28.9%) had the test stimulation lead(s)
removed and replaced with new leads. Nearly all subjects (n5 44;
97.8%) had two leads implanted. Lead type used was fairly split
between wide-spaced four-contact (n5 47; 52.8%) and wide-spaced
eight-contact leads (n5 40; 44.9%). The first lead was placed verti-
cally in 25 subjects (55.6%), horizontally in 17 (37.8%) subjects, and
diagonally for 3 (6.7%) subjects; results were similar for the second
lead. The first lead was placed in the center or within of the area of
pain in 31 subjects (68.9%), bracketing in 6 (13.3%) subjects, lateral in
6 (13.3%) subjects, and medial for 2 (4.4%) subjects; results were sim-
ilar for the second lead. Most subjects (n5 34; 75.6%) were
implanted with a nonrechargeable neurostimulator (Model 37702 or
97702 PrimeAdvancedVR , Medtronic, Minneapolis MN, USA). Percent
of paresthesia coverage was not directly collected within the study;
however, an exploratory analysis can be made by overlapping the
pain map and paresthesia maps. Considering those subjects who
underwent permanent implant, had both pain map and paresthesia
map data available, and were receiving stimulation and indicated
feeling paresthesia at implant (n5 24), nine (37.5%) had 100% over-
lap of pain map boxed areas ticked and paresthesia map boxed areas
ticked, two (8.3%) subjects had 70–79% overlap, seven (29.2%) had
50–59% overlap, five (20.8%) had 1–50% overlap, and one (4.2%)
had no overlap. It should be noted that maps were used to indicate
pain or paresthesia somewhere within the numbered boxed area.
Conclusions cannot be drawn regarding the quality or intensity of
the pain, nor how much of the boxed area had pain or paresthesia.
Programing parameters were left open to the study investigator,
with the exception that rate must not exceed 300 Hz. The goal of
programing was to obtain a comfortable paresthesia feeling over
the painful area. Programing at trial and implant were similar. For
those subjects permanently implanted, most subjects (n5 34; 75.6%)
had Group A set with one to two programs. Mean frequencies were
set between 54.26 26.3 Hz and 55.56 25.3 Hz. Program 1 was set
with a mean pulse width of 307.6 msec6 97.8 and mean amplitude
of 2.1 volts6 1.6. Program 2 was set with a mean pulse width of
289.2 msec6 98.3 and mean amplitude of 2.1 volts6 1.9. In most
subjects (85.3%), cycling was programed off and a soft start (ramp
up) was set at 4 sec. At last reported visit in the 45 permanently
implanted, most subjects (n5 40; 88.9%) continued to have Group A
set with one to two programs. Mean frequencies were set between
51.3 Hz and 65.3 Hz. Program 1 was set with a mean pulse width of
335.3 msec6 87.9 and mean amplitude of 2.3 volts6 2.3. Program 2
was set with a mean pulse width of 320.4 msec6 86.4 and mean
amplitude of 2.9 volts6 2.4.
Primary Endpoint—Responder Rate at Nine Months
For the primary outcome, the responder rate (50% reduction in
back pain intensity) in the SQS1OMM arm was 33.9% (n5 19; 95%
confidence interval [21.5–46.3%]) compared to 1.7% (n5 1; 95%
confidence interval [0.0–4.9%]) in the OMM arm in the ITT analysis
(Fig. 2, Table 2). The difference between arms in the ITT analysis is
statistically significant (Fisher’s exact test—p< 0.0001). When remov-
ing missing data due to early study termination, the responder rate
in the SQS1OMM arm is 52.8% (95% confidence interval [36.5–
69.1%]) compared to 2.8% (95% confidence interval [0.0–8.1%]). In
the PT analysis, the difference in responder rates was also statistically
significant with 56.7% (95% confidence interval [38.9–74.4%]) and
2.9% (95% confidence interval [0.0–8.4%]) in the SQS1OMM and
OMM arms, respectively (Fisher’s exact test—p< 0.0001) (Fig. 3).
Results were similar in the worst case modified ITT analysis with
Figure 2. a. Primary endpoint responder rate by treatment groups: ITT (n5 116). b. ITT—considering only patients who had the chance to reach Month 9 visit.
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responder rate in the SQS1OMM arm of 33.9% (95% confidence
interval [21.5–46.3%]) compared to 1.7% (95% confidence interval
[0.0–4.9%]) (Fisher’s exact test—p< 0.0001).
Secondary Endpoints—Pain Intensity and Responder Rates at
Six and Nine Months
The mean baseline VAS scores were similar in both arms, 68.8 mm
(SD5 13.4; n5 56) and 70.2 mm (SD5 14.0; n5 60) in SQS1OMM
and OMM arms, respectively. In the SQS1OMM arm, the mean
back pain score was reduced to 38.4 mm (SD5 24.5; n5 40) at six
months and 36.9 mm (SD5 24.0; n5 36) at nine months, whereas in
the OMM arm, scores remained stable at 69.8 mm (SD5 18.2;
n5 40) at six months and 67.5 mm (SD5 18.1; n5 36) at nine
months (Fig. 4). The mean absolute change from baseline to nine
months observed in the SQS1OMM arm was 233.3 mm
(SD5 24.5) compared to22.7 mm (SD5 16.0) in the OMM arm (Lin-
ear model adjusted for pain intensity at baseline—p< 0.0001). The
percent reduction in absolute back pain intensity from baseline to
nine months observed in the SQS1OMM arm was 47.0%
(SD5 32.3) compared to 2.5% (SD5 22.9) in the OMM arm (Table 3).
At the six-month visit, the responder rate of 50% reduction in
back pain intensity was 26.8% (15/56) in the SQS1OMM arm com-
pared to 1.7% (1/60) in the OMM arm in the ITT analysis (Fisher’s
exact test—p 5 0.0002) (Table 3). In the PT analysis, the responder
rate in the SQS1OMM arm was 40.0% compared to 2.9% in the
OMM arm (Fisher’s exact test—p5 0.0003). The responder rate of
30% reduction in back pain intensity at the nine-month visit, was
44.6% (25/56) with SQS1OMM compared to 5.0% (3/60) with OMM
(Fisher’s exact test—p< 0.0001) in the ITT analysis. In the PT analysis,
the responder rate is 70.0% with SQS1OMM compared to 11.4%
with OMM alone (Fisher’s exact test—p< 0.0001).
Additional Measures
A statistically significant treatment effect favoring SQS1OMM
was found for disability (ODI index, p< 0.0001), the quality of life
index (EQ-5D-5L index, p5 0.0003), and PGIC (Fisher’s exact test—
p< 0.0001) when compared to OMM alone (Table 4). Subjects in
both arms would recommend their treatment to patients suffering
from similar pain and based on their experience, would agree to
their treatment again; however, no difference between arms was
observed at nine months (Fisher’s exact test—p5 0.547 and
p5 0.644, respectively). The quality of life evaluated with the SF-36
showed a greater improvement in the SQS1OMM arm in the men-
tal component score (p5 0.0062), but not in the physical compo-
nent score (p5 0.293) compared to OMM alone. There was no
difference between arms in the mean change in leg pain intensity
(p5 0.543).
Safety
The safety patient set consisted of all subjects of the ITT analysis
set who started any of the study procedures, independent of the
treatment to which they had been randomized (n5 115). One indi-
vidual stopped the study directly after randomization due to inclu-
sion/exclusion criteria not met. The 51 subjects who were
randomized to SQS1OMM and received the permanent implant
were exposed to the SQS device for a total of 24,508 days, or a
mean of 480.56 297.8 days. A further 28 subjects who were ran-
domized to OMM and later crossed over (post-nine-month visit) and
received the permanent implant, were exposed to the SQS device
for a total of 8433 days, or a mean of 301.26 265.3 days.
There were 193 events reported throughout the study period up
to the 36-month visit, 103 in the SQS1OMM arm and 90 in the
OMM arm. Of the 193 total events, 178 were adverse events and 7
were judged to be device deficiencies only. Eight additional device
deficiencies were associated with an adverse event. Forty-nine sub-
jects experience at least one adverse event: 29 (52.7%) in the
SQS1OMM arm and 20 (33.3%) in the OMM arm. The majority of
Table 2. Primary Outcome of Responder Rate (50% Pain Relief at Nine Months).
Analysis of back pain SQS1OMM OMM Between-group
difference p-value
Total (N) Missing (N, %) Responder (N, %) Total (N) Missing (N, %) Responder (N, %)
ITT 56 20 (35.7%) 19 (33.9%) 60 24 (40.0%) 1 (1.7%) <0.0001
Per-treatment 30 0 (0%) 17 (56.7%) 35 0 (0%) 1 (2.9%) <0.0001
Modified ITT 56 10 (17.9%) 19 (33.9%) 60 24 (40.0%) 1 (1.7%) <0.0001
Figure 3. Analyses of primary endpoint. Fisher’s exact test two-tailed. aPer-
centage (%) considers missing value, responder, and nonresponder.
Figure 4. Mean back pain intensity over time by treatment groups: ITT
(n5 116), means6 SEM. ** p< 0.0001.
ELDABE ET AL.
www.neuromodulationjournal.com VC 2018 The Authors. Neuromodulation: Technology at the Neural Interface Neuromodulation 2018; ••: ••–••
published by Wiley Periodicals, Inc. on behalf of International Neuromodulation Society.
6
www.neuromodulationjournal.com
published by Wiley Periodicals, Inc. on behalf of International Neuromodulation Society.
© 2018 The Authors. Neuromodulation: Technology at the Neural Interface Neuromodulation 2019; 22: 519–528
524
.
events (67.2%) were categorized as “other” etiology (i.e., not etiology
of biological, hardware, therapy, human factors, or medication)
(Fig. 5). The second most frequent etiology was medication (18.3%),
followed by biological-related (7.5%), hardware-related (2.7%), and
therapy-related (2.2%). The most common adverse events occurring
in at least 5% of subjects were back pain (7.0%) and pain in
extremity (5.2%). Across all 80 implanted subjects (SQS1OMM and
OMM alone who later crossed over), a total of four (5.0%) device or
implant related-infections occurred, three (3.8%) lead fractures (two
noted during the implant procedure and one lead damage postim-
plant), and two (2.5%) lead dislocation/migrations. There were no
cases of lead erosion or subject death.
DISCUSSION
This is the first RCT comparing the addition of SQS to OMM alone
and the largest RCT of SQS for the treatment of the low back pain of
FBSS.
Although the study was terminated early with 116 subjects ran-
domized (original target sample size314), the primary and second-
ary objectives of the study were met. Compared to OMM alone, the
SQS1OMM arm has a statistically significant greater proportion of
subjects with a 50 and 30% reduction in back pain intensity
from baseline to the six- and nine-month follow-up visits. Further-
more, the SQS1OMM arm showed a greater mean decrease in
back pain intensity from baseline to the six- and nine-month follow-
up visits than compared to OMM alone. As chance to complete six-
and nine-month follow-up visits was not given to all subjects, we
show a lower responder rate in the ITT analysis due to missing data
for more than a third of subjects. Despite the large number of
adverse events reported, the vast majority were unrelated to the
Table 3. Secondary Outcomes.
Analysis Arm: p-value
SQS1OMM OMM
Mean reduction in back pain intensity between baseline and follow-
up: ITT; relative difference [%]
At nine months (n5 72) 47.0%6 32.3 2.5%6 22.9 <0.0001
At six months (n5 80) 45.6%6 32.1 0.3%6 21.1 <0.0001
At three month ad
hoc (n5 90)
52.4%6 35.2 2.5%6 23.3 <0.0001
Responder rate (50% reduction) (N, %)
At six months (n5 116), ITT 15 (26.8%) 1 (1.7%) 0.0002
At six months (n5 65), PT 12 (40.0%) 1 (2.9%) 0.0003
Responder rate (30% reduction) (N, %)
At nine months (n5 116), ITT 25 (44.6%) 3 (5.0%) <0.0001
At nine months (n5 65), PT 21 (70.0%) 4 (11.4%) <0.0001
Table 4. Additional Outcomes.
Additional measure SQS1OMM OMM alone Between group
p-value*
Baseline Nine months Absolute change
from baseline
[%, SD]
Baseline Nine months Absolute
change from
baseline [%, SD]
Oswestry disability index mean (SD)†
ITT 51.96 13.2 42.16 18.0 212.46 16.5 47.16 11.8 46.66 11.6 20.16 8.3 <0.0001
PT 52.86 12.1 40.76 15.2 212.16 16.3 47.06 11.5 46.76 12.3 20.36 8.1 <0.0001
SF-36 physical component score mean (SD)‡
ITT 28.56 6.3 30.46 6.3 2.16 6.4 30.26 5.2 30.46 5.6 1.06 5.2 0.293
PT 29.06 5.9 30.36 6.4 1.26 5.7 29.26 5.7 30.36 5.6 1.16 5.3 0.335
SF-36 mental component score mean (SD)‡
ITT 42.06 10.9 44.86 11.5 3.86 11.3 45.26 11.1 45.46 11.1 21.66 8.4 0.0062
PT 41.26 10.1 45.66 10.5 4.46 10.9 47.06 9.9 46.06 11.5 21.06 7.8 0.0359
Leg Pain VAS (SD)†
ITT 8.96 10.8 12.36 17.8 5.26 14.9 6.86 11.5 5.96 11.4 1.06 5.2 0.543
PT 7.26 8.2 8.46 11.8 1.16 8.4 4.66 7.7 8.16 17.6 3.56 12.9 0.045
EQ-5D-5L utility score with a UK value set; mean (SD)‡
ITT 0.406 0.22 0.566 0.29 0.196 0.25 0.436 0.23 0.456 0.22 20.016 0.15 0.0003
PT 0.396 0.20 0.596 0.27 0.206 0.24 0.456 0.22 0.456 0.22 20.006 0.16 <0.0001
Patient global impression of change categories of very much improved and much improved (N, %)
ITT N/A 20 (33.3%) N/A N/A 1 (1.7%) N/A <0.0001
PT N/A 18 (60%) N/A N/A 1 (2.9%) N/A <0.0001
Would recommend their treatment to patients suffering similar pain (Yes: N, %)
ITT N/A 33 (58.9%) N/A N/A 29 (48.3%) N/A 0.547
PT N/A 27 (90.0%) N/A N/A 27 (77.1%) N/A 0.2012
Based on experience, would agree to their treatment again (Yes: N, %)
ITT N/A 29 (48.3%) N/A N/A 32 (57.1%) N/A 0.644
PT N/A 27 (90.0%) N/A N/A 27 (77.1%) N/A 0.2012
*Between group p-value of treatment effect in linear regression model.
†A negative change indicates an improvement in between baseline and follow-up visits.
‡A positive change indicates an improvement in between baseline and follow-up visits.
ITT, intent-to-treat; N/A, not applicable; PT, per-treatment; SD, standard deviation; VAS, visual analog scale.
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device or therapy. Events with an etiology of pain medications were
more frequently reported than those associated with the implant
procedure, device or therapy.
Our study adds to the limited literature on PNFS or SQS in
patients with predominant to pure back pain. The only other RCT of
PNFS alone was published by McRoberts et al. in 2013 (12) where 32
subjects were randomized to various programing settings applied
during the trial phase. Long-term follow-up was observational in
nature. At one-year follow-up, significant differences in VAS scores
were observed between baseline and all follow-up visits. While a sta-
tistically significant improvement in SF-36 PCS was observed, the
study failed to demonstrate significant improvement in SF-36 MCS.
A number of case series reported positive outcomes of PNFS
(10,11,13–16). Sator-Katzenschlager et al. (2010) described a retro-
spective case series of 111 implanted, chronic pain patients. Pain
intensity was reduced in 92% of patients at three-month follow-up
(14). Kloimstein et al. (2014) reported a 118 patient prospective
series examining the effectiveness of PNFS alone or in combination
with SCS to treat chronic back pain (11). Of the 40 implanted with
PNFS alone, 28 completed the six-month visit and showed a statisti-
cally significant improvement in back pain intensity compared to
baseline. Finally, Verrills et al. (2011) reported the outcomes of 100
consecutive private practice patients receiving PNFS for the treat-
ment of chronic pain of various etiologies (15). The authors demon-
strated an average pain reduction of 4.26 2.5 pain scale points on
an 11-point scale following PNFS (preimplant pain score of 7.46 1.7)
over a follow-up period of 8.16 4.7 months (range 1–23 months).
Of the 100 cases, 44 were reported to be suffering from lumbosacral
pain.
These studies show relatively similar results for improvement in
pain intensity in PNFS patients, reducing from a baseline range
between 7.4 and 8.0 (on 0–10 scale), to between 3.2 and 4.7 at
follow-up visits (11,12,14,15). For our study, mean pain scores in the
SQS1OMM arm started slightly lower (baseline 68.8 mm on
100 mm VAS), but reduced to 33.3, 38.4, and 36.9 mm at three-, six-,
and nine-month visits, respectively. The ODI improvement ranged
from 11.2 to 12.5 points, depending on the follow-up visit (Month 3,
6, or 9; ITT set), whereas the Kloimstein et al. trial showed a smaller
reduction from 38.2 at baseline to 34.6 at six months. For quality of
life SF-36, our study fell short of the improvements seen in the litera-
ture for the PCS; however, surpassed literature in the MCS. Overall,
our treatment arm results align well with these published studies.
Compared to SCS, the responder rate to PNFS therapy is limited,
for example the PROCESS study randomized 100 FBSS patients to
receive SCS and Conventional Medical Management (SCS Group) or
conventional medical management alone (CMM Group) reported an
ITT responder rate of 48% at six months, higher than our responder
rate of 34% reported at nine months (8). Caution should be taken in
direct comparisons of the ITT responder rate of this study to other
trials as ours is restricted by the limited number of subjects having
the opportunity to complete the nine-month follow-up. An impor-
tant comparison is the simplicity of the implant technique as well as
enhanced safety profile compared to SCS. In our study across 80
implanted patients, there were four (5%) infections, three (3.8%)
lead fractures (two of these occurred during the implant procedure),
and only two (2.5%) lead migrations compared to 4/42 infections
(10%) and 6/42 lead migrations (14%) and 3/42 lead fractures (7%)
in the PROCESS study at 24 months (22). While the low adverse
event figures partially reflect hardware improvement, they also in
our opinion reflect the simplicity of the technique. Furthermore, the
absence of epidural space access will provide an attractive option
for a subgroup of patients with concerns about spinal cord damage
or those with existing epidural scarring.
The improvement in the disability index, the quality of life and
the global impression of change observed in the SQS1OMM arm is
in contrast with the fact that patients of both arms would similarly
recommend their treatment to patients suffering from similar pain
or would agree to the same treatment again. This finding is not
uncommon and might be due to a “study effect” whereby patients
express their satisfaction as a result of being managed, regardless of
the actual efficacy of the treatment, as was observed before (23).
Both SCS and SQS are believed to provide pain relief by activation
of non-nociceptive Aß fibers, while the activation of Ad fibers will
produce pain. Morch et al. have proposed a mathematical model of
SQS based on the anatomy of the skin and subcutaneous tissue (24).
The model predicts an optimal implantation depth of 10–15 mm
below the skin surface to achieve activation of the greatest area of
Aß fibers and the smallest area of Ao fibers. Using a similar computa-
tional model, Frahm et al. have found the lowest threshold of Aß
fibers when nerve and electrode were in parallel, with currents
within therapeutic range (<10 V) of PNFS (25).
Vera-Portocarrero et al. (2013) used rodent models of inflamma-
tory and neuropathic pain to investigate subcutaneous electrical
stimulation (SQS) vs. transcutaneous electrical nerve stimulation
(TENS) (26). The rodent model of subcutaneous stimulation was
compared to a rodent TENS model, since an argument could be
made that SQS is just “TENS under the skin.” When comparing both
models, there were differences in the effects of each therapy modal-
ity on rodent models of neuropathic pain and inflammatory pain.
SQS was effective in the neuropathic pain and had cumulative
effects on hyper sensitivity of both inflammatory and neuropathic
pains with reduction mechanical hypersensitivity observed on
Days 3 and 4, thermal hyperalgesia in first four days and reductions
in cold allodynia observed only in the first day of stimulation. In con-
trast TENS was effective in the inflammatory model only and toler-
ance to its antihypersensitivity effects developed with time. These
results indicated that SQS and TENS act through difference mecha-
nism of action.
Further characterization was done with the SQS model. The
importance of the location of the lead implant was demonstrated
by determining that implantation of the subcutaneous lead in the
Figure 5. Adverse event etiology.
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primary area of injury was necessary to have effectiveness (27). Addi-
tionally, the length of stimulation and the amplitude of stimulation
influence the amount of effectiveness that SQS has in a rodent
model of neuropathic pain (28,29). Mainly the longer the stimulation
and the higher the amplitude, the greater the effectiveness.
These results demonstrate that SQS produces anti-nociceptive
effects in rats with nerve injury. Parameter optimization becomes
clearly important since in the rodent model, location, length, and
amplitude are critical parameters for the effectiveness of SQS.
Results point to different mechanism being involved for the effects
of SQS and TENS. This novel model of SQS as a therapy for pain can
be used for further translational mechanistic studies.
STUDY STRENGTHS AND LIMITATIONS
This study was designed to be a pragmatic trial to demonstrate
the real-world effectiveness of SQS therapy in addition to OMM in
FBSS patients with chronic back pain and little to no radicular leg
pain. The multicenter participation across Europe, Israel, and Austra-
lia, support the generalizability of the results.
The study had a number of potential limitations. First, blinding
was not feasible in a comparative study vs. nonsurgical intervention.
To minimize the placebo effect of receiving SQS therapy, the pri-
mary endpoint was assessed at nine months, rather than the more
commonly used three- or six-month time points.
Second, subjects enrolled in the study could be considered to
have already failed OMM upon enrollment and by definition of FBSS
and study criteria, subjects have previously tried at least three treat-
ments for their back pain. Thus a significant improvement in the
OMM alone arm may not be expected. To guard against treatment
bias, investigators were instructed to optimize medical management
for all study subjects. Third, the decision to terminate early resulted
in a smaller number of patients contributing to the final ITT analysis,
which potentially limits the conclusions that can be reached from
the study. However, the overall alpha error risk for study was main-
tained at 5%.
Finally, the study is not able to inform on the long-term effective-
ness of SQS. While the study initially planned to follow all patients
for 36 months, only four reached that follow-up point.
CONCLUSIONS
This is the largest multicenter RCT comparing OMM to
SQS1OMM in patients with back pain due to FBSS. Despite early
termination due to recruitment difficulties, the results indicate that
the addition of SQS to OMM is clinically and statistically more effec-
tive than OMM alone in relieving low back pain at up to nine
months. These findings support the results of a number of earlier
uncontrolled case series.
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